Latest Regulatory News

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Aguia Resources has updated its NI 43-101 report on the Atocha Project in Colombia, revealing impressive historic gold and silver grades and announcing imminent surface exploration to unlock further potential.

Zeotech Limited’s Preliminary Feasibility Study (PFS) for its AusPozz™ Project reveals a robust business case for Australia’s first metakaolin production facility, promising strong financial returns and significant carbon emission reductions.

Findi Limited has appointed DAM Capital and Ambit as lead managers for the IPO of its Indian subsidiary, Transaction Solutions International, targeting a valuation near A$900 million and a 2026 listing.

St George Mining secures robust local and state government support for its Araxá rare earths and niobium project in Brazil, launching community programs and accelerating exploration activities.

Constellation Resources has identified a significant gold-copper soil anomaly named Chatham at its Ularring Project in Western Australia, shifting exploration focus to this promising new target.

Capricorn Metals has extended its mining contract with MACA Ltd for Karlawinda and named MACA preferred contractor for Mt Gibson, locking in cost certainty and supporting production growth.

DeSoto Resources has reported promising high-grade gold assay results from a recent shallow power auger drilling program at its Dadjan Gold Project in Guinea’s prolific Siguiri Basin. The findings confirm extensive gold anomalism along key structural trends, reinforcing the project’s exploration potential.

Collins Foods delivered resilient FY25 results with solid revenue growth and a strategic pivot towards German market expansion, while addressing profitability challenges in the Netherlands.

Collins Foods reported a record $1.52 billion revenue for FY25 with flat EBITDA despite tough market conditions, while signaling optimism for low to mid-teens NPAT growth in FY26.

Collins Foods Limited reported record revenue of $1.52 billion for FY25, up 2.1%, but statutory net profit plunged 88.5% due to significant impairments and wage provisions. The company declared a fully franked final dividend of 15 cents per share, signaling confidence despite challenges.

Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.